National Academies Press: OpenBook

Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (2003)

Chapter: Appendix C: Chronology of Important Events Regarding Vaccine Safety

« Previous: Appendix B: Agenda
Suggested Citation:"Appendix C: Chronology of Important Events Regarding Vaccine Safety." Institute of Medicine. 2003. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. doi: 10.17226/10534.
×
Page 98
Suggested Citation:"Appendix C: Chronology of Important Events Regarding Vaccine Safety." Institute of Medicine. 2003. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. doi: 10.17226/10534.
×
Page 99
Suggested Citation:"Appendix C: Chronology of Important Events Regarding Vaccine Safety." Institute of Medicine. 2003. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. doi: 10.17226/10534.
×
Page 100
Suggested Citation:"Appendix C: Chronology of Important Events Regarding Vaccine Safety." Institute of Medicine. 2003. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. doi: 10.17226/10534.
×
Page 101
Suggested Citation:"Appendix C: Chronology of Important Events Regarding Vaccine Safety." Institute of Medicine. 2003. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. doi: 10.17226/10534.
×
Page 102

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

955 963 967 971 977 979 982 Appendix C Chronology of Important Events Regarding Vaccine Safety Year Vaccine Licensure Legislation and/or TOM Reports on Policy Statements Vaccine Safety Activated poliomyelitis vaccine (IPV) available Oral poliomyelitis vac- cine (OPV) available, replaces IPV Measles vaccine available Mumps vaccine available Rubella vaccine available Measles -Mump s-Rubella (MMR) vaccine available Current formulation of rubella vaccine available, replaces earlier versions Plasma-derived hepatitis B vaccine available 1985 Hib vaccine licensed for Mumps vaccination recommended Evaluation of Poliomyelitis Vaccines 98

APPENDIX C 99 Year Vaccine Licensure Legislation and/or TOM Reports on Policy Statements Vaccine Safety children >15 months 1986 1988 990 991 1992 1993 1994 Acellular pertussis com- ponent licensed for the 4 and So doses of the S-part DTP series in Tripedia Combined DTP and Hib vaccine (Tetramune) licensed 1995 Varicella virus vaccine available (Varivax) Congress passes Public Law 99-660, the National Child- hood Vaccine Injury Act (in- troduced in 1984) calls for: · est. of NVPO est. of NVAC est. of VICP est. of ACCV IOM review of 1 ) pertussis and rubella, 2) routine child vac- cines 2 Hib conjugate vaccines licensed for use begin- ning at 2 months Evaluation of Polio- myelitis Vaccine Policy Options Acellular pertussis com- Hepatitis B recommended by Adverse Ejects of portent licensed for the Oh ACIP for addition to childhood Pertussis and Ru- and 5~ doses of the 5-part immunization schedule bella Vaccines DTP series in ACEL- IMUNE ACIP recommends Hib be added to childhood immuniza- tion schedule Hepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons win multiple sex parmers) Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality DPT and Chronic Nervous System Dysfunction: A New Analysis

100 I M M U N I Z A T I O N S A F E T Y R E V I E W Year Vaccine Licensure Legislation and/or Policy Statements ACIP recommends using IPV for the first 2 polio vaccina- tions, followed by OPV for remaining doses. Intended to be a transitional schedule for 3-5 years until an all-IPV series is available TOM Reports on Vaccine Safety Options for Polio- myelitis Vaccinations in the United States: Workshop Summmy 996 997 998 999 DTaP vaccine licensed for first three doses given in infancy (Tripedia and ACEL-IMUNE were previously licensed for only the 4~ and 5th doses). Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part series Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part series Additional supply of thimerosal-free hepatitis B vaccine made available 2000 Pneumococcal vaccine for infants and young ACIP recommends children 12months - 12 years receive Varicella vaccine ACIP recommends DTaP in place of DTP ACIP updates MMR recom- mendation, encouraging use of the combined ME vaccine ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry ACIP recommends an all-IPV schedule begin January 2000 to prevent cases of vaccine- associated paralytic polio AAP and PHS recommend removal of thimerosal from vaccines Also recommended postpone- ment of hepatitis B vaccine from birth to 2-6 months for infants of hepatitis B surface antigen-negative mothers MOOR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose AC IP recommends p neumo - coccal vaccination for all Vaccine Safety Fo- rum: Summary of Two Workshops Risk Communication and Vaccination: Workshop Summary

APPENDIX C 101 Year Vaccine Licensure Legislation Policy Statements and/or TOM Reports on Vaccine Safety 2001 2002 children licensed (Prev- children 2-23 months, and at- nar) risk children 2059 months (e.g., immunocompromised) October: ACIP drafts statement Immunization Safety expressing a preference for use Review: Measles- of thimerosal-free DTaP, Hib, Mumps-Rubella and Hep B vaccines by March Vaccine and Autism 2002 Immunization Safety Review: Thimerosal- Containing Vaccines and Neurodevelop- mental Disorders Immunization Safety Review: Multiple Immunizations and Immune Dysfunction Immunization Safety Review: Hepatitis B Vaccine and Demye- linating Neurological Disorders

Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The Immunization Safety Review Committee was established by the Institute of Medicine (IOM) to evaluate the evidence on possible causal associations between immunizations and certain adverse outcomes, and to then present conclusions and recommendations. The committee's mandate also includes assessing the broader societal significance of these immunization safety issues. While all the committee members share the view that immunization is generally beneficial, none of them has a vested interest in the specific immunization safety issues that come before the group. The committee reviews three immunization safety review topics each year, addressing each one at a time. In this fifth report in a series, the committee examines the hypothesis that exposure to polio vaccine contaminated with simian virus 40 (SV40), a virus that causes inapparent infection in some monkeys, can cause certain types of cancer.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!